COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Cambridge Cardiovascular Seminar Series > Prescribing step counts in type 2 diabetes and hypertension:Results of the Step Monitoring to improve ARTERial health trial
Prescribing step counts in type 2 diabetes and hypertension:Results of the Step Monitoring to improve ARTERial health trialAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact vr314. Strong evidence demonstrates that low walking levels predict the development of type 2 diabetes and the development of diabetes-related complications and mortality among individuals with established type 2 diabetes. While large-scale observational studies have relied on self-reported weekly time spent walking as the main walking measure, some more recent studies have used step counters (pedometers and accelerometers) that measure steps throughout the day, both those performed ‘incidentally’ and those performed explicitly for exercise. Step counting has been shown to be effective in self-monitoring and goal setting in physical activity programs for type 2 diabetes and other chronic conditions. However, most of these programs are ‘not universally available. In the Step Monitoring to improve ARTE Rial health trial (SMARTER; funded by the Canadian Institutes of Health Research), active arm participants tracked their step counts, reviewed their step count records with their doctors, and then set step targets; the doctor then provided a written and signed prescription. We showed that this approach led to higher step counts, lower hemoglobin A1C , and lower insulin resistance. Results have been published in the journal Diabetes, Obesity & Metabolism (2017) (open access). During this presentation, we will discuss the evidence that led to the SMARTER trial, describe the SMARTER strategy, and the findings from the trial. We will also share some of the facilitators and barriers that we identified following the trial, through discussions with collaborating physicians and trial participants. This talk is part of the Cambridge Cardiovascular Seminar Series series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsInternational Women's Week at Wolfson Making Visible project events Sustainability Leadership LaboratoriesOther talksGraph Convolutional Networks for Natural Language Processing and Relational Modeling Inelastic neutron scattering and µSR investigations of an anisotropic hybridization gap in the Kondo insulators: CeT2Al10 (T=Fe, Ru and Os) Nonlinear nonmodal stability theory Disabled Academics in the 21st Century: 15th Annual Disability Lecture Seminar – Why do policymakers seem to ignore your evidence? How to know Africa(s) in an age of youth hybridity |